Stocktoria

BioScience Health Innovations, Inc. BHIC

BioScience Health Innovations, Inc. financials (annual, from 10-K)

Revenue
2020202120222022202320242025
Net income
2020202120222022202320242025
Free cash flow
2020202120222022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2022FY2021FY2020
Revenue$5.7M$1.8M$597,595$69,343$0$0$0
Gross profit$3.2M$1.3M$484,407$59,644
R&D expense$37,540$25,908$0
SG&A expense$2.2M$1.1M$706,257$151,319$91,921$25,610$7,682
Operating income$719,051$87,000-$251,500-$170,450-$91,921-$25,610-$7,682
Interest expense$450
Income tax$76,961$0$0$0$0$0$0
Net income$642,090$87,000-$251,500-$170,450-$83,208-$25,610-$7,682
EPS (diluted)$0.06$0.01$-0.01
Operating cash flow$172,178$23,188-$307,842-$182,779-$85,782-$29,439-$7,682
Cash & equivalents$661,925$662,517$19,238$11,569$2,035$20,629
Inventory$336,348$58,319$37,702$12,278
Total assets$1.7M$873,788$93,388$31,608$16,253$6,314$20,629
Total liabilities$229,851$38,548$100,148$48,791$1,860$19,106$7,811
Shareholders' equity$1.5M$835,240-$6,760-$17,183$14,393-$12,792$12,818

Growth · year-over-year

MetricFY2025FY2024FY2023FY2022FY2022FY2021FY2020
Revenue growth+208.3%+208.7%+761.8%
Net income growth+638.0%
EPS growth+500.0%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Source: SEC EDGAR filings · CIK 0001784440 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.